• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CareDx Inc. (Amendment)

    2/13/24 10:17:49 AM ET
    $CDNA
    Medical Specialities
    Health Care
    Get the next $CDNA alert in real time by email
    SC 13G/A 1 d749646dsc13ga.htm SC 13G/A SC 13G/A

     

     

    United States

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    CareDX, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    14167L103

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 14167L103

     

     1.   

     Names of Reporting Persons

     

     Bellevue Asset Management (UK) Ltd.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     England and Wales

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    with:

       5.   

     Sole Voting Power

     

     0

       6.  

     Shared Voting Power

     

     3,954,792

       7.  

     Sole Dispositive Power

     

     0

       8.  

     Shared Dispositive Power

     

     3,954,792

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,954,792

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11.  

     Percent of Class Represented by amount in Row (9)

     

     7.3%

    12.  

     Type of Reporting Person (See Instructions)

     

     FI

     

    2


    CUSIP No. 14167L103

     

     1.   

     Names of Reporting Persons

     

     Bellevue Group AG

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Switzerland

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    with:

       5.   

     Sole Voting Power

     

     0

       6.  

     Shared Voting Power

     

     3,954,792

       7.  

     Sole Dispositive Power

     

     0

       8.  

     Shared Dispositive Power

     

     3,954,792

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,954,792

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11.  

     Percent of Class Represented by amount in Row (9)

     

     7.3%

    12.  

     Type of Reporting Person (See Instructions)

     

     CO, HC

     

     

    3


    Item 1

    1(a) Name of Issuer: CareDX, Inc.

    1(b) Address of Issuer’s Principal Executive Offices:

    3260 Bayshore Boulevard, Brisbane, CA 94005

    Item 2

    2(a) Name of Person Filing: Bellevue Group AG (“Bellevue Group”) on behalf of its wholly-owned subsidiary, Bellevue Asset Management (UK) Ltd. (“Bellevue Asset Management”).

    2(b) Address of Principal Business Office or, if none, Residence:

    Bellevue Asset Management (UK) Ltd.: 32 London Bridge Street, 24th Floor, London, England SE1 9SG

    Bellevue Group AG:  Seestrasse 16, Kuesnacht, Switzerland, CH-8700

    2(c) Citizenship: Bellevue Asset Management (UK) Ltd.: England and Wales

    Bellevue Group AG: Switzerland

    2(d) Title of Class of Securities: Common Stock

    2(e) CUSIP Number: 14167L103

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned: 3,954,792

     

      (b)

    Percent of class: 7.3%

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote 0

     

      (ii)

    Shared power to vote or to direct the vote 3,954,792

     

      (iii)

    Sole power to dispose or to direct the disposition of 0

     

      (iv)

    Shared power to dispose or to direct the disposition of 3,954,792

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    This statement is filed jointly by Bellevue Asset Management and Bellevue Group. Bellevue Asset Management is a wholly-owned subsidiary of Bellevue Group.

     

    4


    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    By signing below I also certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to investment advisers and investment companies is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

    SIGNATURES

    After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Bellevue Asset Management (UK) Ltd.    
    Date: February 12, 2024     By:  

    /s/ Martin Gubler

          Signatory Authority
        Name:   Martin Gubler
        Title:   Director
    Bellevue Group AG    
    Date: February 12, 2024     By:  

    /s/ Michael Hutter

          Signatory Authority
        Name:   Michael Hutter
        Title:   Chief Financial Officer
    Date: February 12, 2024     By:  

    /s/ Christoph Eisenring

          Signatory Authority
        Name:   Christoph Eisenring
        Title:   Head Legal & Compliance

     

    5


    Exhibit Index

    Exhibit A: Agreement by and between Bellevue Asset Management (UK) Ltd. and Bellevue Group AG with respect to the filing of this disclosure statement.*

     

    *

    Previously filed as an exhibit to Bellevue Asset Management (UK) Ltd. and Bellevue Group AG’s Schedule 13G filed with the Securities and Exchange Commission on February 14, 2023.

     

    6

    Get the next $CDNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDNA

    DatePrice TargetRatingAnalyst
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$28.00Underweight
    Wells Fargo
    8/19/2024$40.00Neutral → Buy
    BTIG Research
    5/13/2024Outperform → Mkt Perform
    Raymond James
    5/1/2024$15.00Hold → Buy
    Craig Hallum
    11/9/2023$10.00Equal-Weight → Overweight
    Stephens
    8/15/2023$12.00Mkt Perform → Outperform
    Raymond James
    5/11/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $CDNA
    SEC Filings

    View All

    SEC Form 10-Q filed by CareDx Inc.

    10-Q - CareDx, Inc. (0001217234) (Filer)

    8/6/25 4:11:48 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Leadership Update, Regulation FD Disclosure

    8-K - CareDx, Inc. (0001217234) (Filer)

    8/6/25 4:08:05 PM ET
    $CDNA
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by CareDx Inc.

    SCHEDULE 13G - CareDx, Inc. (0001217234) (Subject)

    7/24/25 4:28:16 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Smith Nathan was granted 42,000 shares (SEC Form 4)

    4 - CareDx, Inc. (0001217234) (Issuer)

    8/11/25 4:35:25 PM ET
    $CDNA
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Smith Nathan

    3 - CareDx, Inc. (0001217234) (Issuer)

    8/11/25 4:34:16 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Secretary and General Counsel Novack Jeffrey Adam sold $34,381 worth of shares (2,688 units at $12.79), decreasing direct ownership by 2% to 112,930 units (SEC Form 4)

    4 - CareDx, Inc. (0001217234) (Issuer)

    8/7/25 4:00:30 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Leadership Updates

    Live Leadership Updates

    View All

    CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

    CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan. Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands. "Nathan's deep f

    8/6/25 4:57:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Appoints Jing Huang Chief Data and AI Officer

    CareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Company's long-term strategic growth plan. CareDx intends to share its long-term growth strategy during an Investor Day on October 15, 2024. Huang is a recognized leader in data science and machine learning, bringing to CareDx a proven trac

    10/9/24 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer

    CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024. Keith Kennedy brings more than 20 years of experience and e

    9/12/24 7:01:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Financials

    Live finance-specific insights

    View All

    CareDx to Report Second Quarter 2025 Financial Results

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-274-8461 for domestic callers or 1-203-518-9814 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, plea

    7/23/25 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx to Report First Quarter 2025 Financial Results

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please

    4/8/25 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx to Report Fourth Quarter and Full Year 2024 Financial Results

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to

    2/11/25 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/14/24 5:13:57 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/8/24 2:34:10 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/5/24 6:07:26 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

    CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan. Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands. "Nathan's deep f

    8/6/25 4:57:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Second Quarter 2025 Financial Results

    Grew Testing Services Volume to Approximately 49,500, Increase of 13% Year-Over-Year AlloSure Kidney Testing Volumes Grew Nearly 20% Year-Over-Year Narrows Full Year 2025 Revenue Guidance to $367 Million to $373 Million CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company - a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported revenue of $86.7 million including a $3.8 million write-off of aged receivables associat

    8/6/25 4:01:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation

    KOAR, the Largest Prospective Study of Its Kind, Demonstrates Clinical Utility of AlloSure® in Kidney Transplant Surveillance AlloSure Kidney dd-cfDNA Elevation Strongly Predicts Rejection and Improves Biopsy Yield CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the publication of the Kidney Allograft Outcomes AlloSure Registry (KOAR) study in the American Journal of Transplantation. The landmark prospective study demonstrates the clinical utility of AlloSure® donor-

    8/6/25 12:56:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CareDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously

    1/15/25 7:29:19 AM ET
    $CDNA
    Medical Specialities
    Health Care

    Wells Fargo initiated coverage on CareDx with a new price target

    Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00

    8/28/24 7:38:28 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx upgraded by BTIG Research with a new price target

    BTIG Research upgraded CareDx from Neutral to Buy and set a new price target of $40.00

    8/19/24 8:49:21 AM ET
    $CDNA
    Medical Specialities
    Health Care